"Anti VEGF" trang 1 - tải miễn phí từ tailieunhanh
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
11    90    1
A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
14    40    1
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: A prospective study with focus on primary tumor sidedness

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: A prospective study with focus on primary tumor sidedness
9    80    0
Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: Final results of a noninterventional study

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: Final results of a noninterventional study
10    44    1
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model

Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model
13    64    1
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
7    39    1
Rapid resolution of severe exudation in uveal effusion syndrome with anti-vascular endothelial growth factor alone in a case of bilateral nanophthalmos: A case report

Rapid resolution of severe exudation in uveal effusion syndrome with anti-vascular endothelial growth factor alone in a case of bilateral nanophthalmos: A case report
10    20    1
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
7    40    1
Isoprenaline/β2-AR activates Plexin-A1/ VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis

Isoprenaline/β2-AR activates Plexin-A1/ VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis
15    41    1
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases
10    67    1
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
13    23    1
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
9    56    1
A VELOUR post hoc subset analysis: Prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

A VELOUR post hoc subset analysis: Prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
9    36    1
EphB4 as a therapeutic target in mesothelioma

EphB4 as a therapeutic target in mesothelioma
7    30    1
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
14    59    1